A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs UB 311 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors United Neuroscience
- 24 Jul 2017 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.
- 24 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
- 10 Jun 2017 Biomarkers information updated